

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 2/00, 14/00, A61K 38/19, 48/00		A1	(11) International Publication Number: WO 00/59928 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/US00/09236 (22) International Filing Date: 6 April 2000 (06.04.00)		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/128,106 7 April 1999 (07.04.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: THOMAS JEFFERSON UNIVERSITY [US/US]; 1020 Locust Street, Philadelphia, PA 19107 (US).			
(72) Inventors: HUANG, Ziwei; South 10th Street #505C, Philadelphia, PA 19107 (US). LUO, Zhaowen; 1000 Walnut Street #1907, Philadelphia, PA 19107 (US). ZHOU, Naiming; 500 Park Boulevard #135C, Cherry Hill, NJ 08002 (US). LUO, Jiansong; 1000 Walnut Street #1108, Philadelphia, PA 19107 (US).			
(74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Suite 1800, Two Penn Center Plaza, Philadelphia, PA 19107 (US).			

(54) Title: CHEMOKINE-DERIVED SYNTHETIC PEPTIDES

(57) Abstract

Synthetic peptide analogs of chemokines are designed to include the N- and C-terminal portions of the corresponding naturally occurring chemokine. In particular, synthetic peptide analogs of stromal cell-derived factor-1 (SDF-1) are effective in inhibiting HIV-1 entry and infection via the CXC chemokine receptor 4 (CXCR4). Each peptide comprises a peptide segment analog of the SDF-1 N-terminal region joined to a peptide segment analog of the SDF-1 C-terminal region. The peptides are useful for HIV treatment and prophylaxis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UC	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

CHEMOKINE-DERIVED SYNTHETIC PEPTIDES

Reference to Government Grant

This invention was made in the course of research sponsored by the National Institutes of Health grant GM57761. The U.S. Government
5 has certain rights in the invention.

Cross-Reference to Related Application

The benefit of the filing date of U.S. provisional patent application Ser. No. 60/128,106, filed April 7 1999, is hereby claimed. The entire disclosure of the aforesaid provisional application is incorporated
10 herein by reference.

Field of the Invention

The invention relates to the field of synthetic peptides derived from chemokines. In particular, the invention relates to antiviral agents useful for inhibiting the infectivity of human acquired immunodeficiency
15 virus. More particularly, the present invention is directed to synthetic peptides capable of inhibiting HIV-1 infection.

Background of the Invention

Chemoattractant cytokines or "chemokines" are a group of proteins characterized by a fairly high degree of amino acid sequence
20 conservation. They are chemoattractants for leukocytes. The chemotactic

effect of substances on leukocytes may be determined by devices such as the chemotaxis chamber invented by Boyden (Boyden, *J. Ex. Med.* 115:453-66, 1962).

Chemokines act on responsive leukocytes subsets through 5 chemokine receptors. Engagement of chemokine receptors results ultimately in the movement of the cell. Chemokine receptors belong to the superfamily of G-protein coupled receptors (GPCR) that possess seven transmembrane helices (Murphy, P.M., *Annu. Rev. Immunol.* 12:593-633, 1994). The three-dimensional structure of chemokine receptors is not 10 known since currently no crystal structure is available for any of GPCR proteins (Strader et al., *Annu. Rev. Biochem.* 63:101-32, (1994); Kobilka, B., *Annu. Rev. Neurosci* 15:87-114, (1992)).

Chemokines are the natural ligands for chemokine receptors and are 8-10 kDa molecules which act as chemoattractants by signaling 15 through their receptors and activating the target cells (Premack et al., *Nature Medicine* 2:1174-8, (1996)). Chemokines may be divided into at least three structural branches: C, CC, and CXC, according to variations in a shared cysteine motif (Schall, *Curr. Opin. Immunol.* 6:865-873, 1994). The CX, also known as α , and the CC, also known as β , are the major 20 classes of chemokines. Most CXC chemokines (those that contain an ELR sequence N-terminal to the CXC motif) are chemoattractants for neutrophils but not monocytes, whereas CC chemokines generally attract monocytes and lymphocytes, but not neutrophils. Basophils and eosinophils are affected predominantly by CC chemokines. The C chemokines appear to 25 be lymphocyte specific.

Stromal-cell-derived factor-1 (SDF-1) is a member of the CXC chemokine family and is the ligand for CXC chemokine receptor 4 (CXCR4) (Tashiro et al., *Science* 261:600-603, (1993); Shirozu et al., *Genomics* 28:495-500, (1995)). The CC chemokines MIP-1 β (macrophage 30 inflammatory protein 1 β), MIP-1 α (macrophage inflammatory protein 1 α)

and RANTES (regulated on activation normal T cell expressed and secreted) bind CCR5.

Human immunodeficiency virus type 1 (HIV-1) enters cells through a fusion process in which the HIV-1 envelope glycoprotein gp 120 binds to CD4, the main receptor for HIV-1 on the cell surface. However, it has been known that CD4 alone is not sufficient for HIV-1 fusion and entry and that additional receptors may be needed (Maddon et al., *Cell* 47:333-348, (1986); Clapham et al., *Virology* 181:703-15, (1991)).

The chemokine receptors CXCR4 and CCR5 have been shown to be the long-sought coreceptors for non-syncytium-inducing and syncytium-inducing HIV-1 strains, respectively (Feng et al., *Science* 272:872-877, (1996); Deng et al., *Nature* 381:661-666, (1996); Dragic et al., *Nature* 381:667-673, (1996); Alkhatib et al., *Science* 272:1955-8, (1996)). While all HIV-1 strains appear to require either CXCR4, CCR5 or both (Zhang et al., *Nature* 383:768, (1996); Simmons et al., *Journal of Virology* 70:8355-60, (1996)), some strains can also use other chemokine receptors CCR3 and CCR2b as coreceptors for fusion and infection (Doranz et al., *Cell* 85:1149-58, (1996); Choe et al., *Cell* 85:1135-48, (1996)).

SDF-1 and CXCR4 play a role in HIV-1 viral entry. The fusion process may involve the initial binding of HIV-1 gp120 to its high-affinity receptor CD4 which results in conformational changes in gp120 and possibly also CD4 (Gershoni et al., *Journal* 7:1185-7, (1993); Clements et al., *AIDS Research & Human Retroviruses* 7:3-16, (1991); Sattentau et al., *Journal of Virology* 67:7383-93, (1993)). The gp120-CD4 complex interacts with CXCR4 or other chemokine coreceptors to form a heterotrimeric complex of gp120-CD4-coreceptor (Lapham et al., *Science* 274:602-5, (1996); Wu et al., *Nature* 6605:179-83, (1996); Trkola et al., *Nature* 384:184-7, (1996)). It has been shown that the HIV envelope can bind CXCR4 independently and that this interaction is enhanced by the presence of CD4 (Bandres et al., *Journal of Virology* 72:2500-2504, (1998)).

On the other hand, it is also known that the CXCR4 ligand, SDF-1 inhibits HIV-1 infection (Bleul et al., *Nature* 382:829-833, (1996); Oberlin et al., *Nature* 382:833-835, (1996)).

Several inhibitors of HIV-1 have been found to target the 5 coreceptor CXCR4 (Murakami et al., *J. Exp. Med.* 186:1389-133, (1997); Schols et al., *J. Exp. Med.* 186:1383-1388, (1997); Donzella et al., *Nature Medicine* 4:72-77, (1998); Doranz et al., *J. Exp. Med.* 186:1395-1400, (1997)). Synthetic peptides derived from SDF-1 have been shown to posses anti-HIV activity (Heveker et al., *Current Biology* 8:369-376 (1998)).
10 While the solution structure of SDF-1 has been determined (Crump et al., *EMBO J.* 16:6996-7007 (1998)), there is no crystal structure available for CXCR4 to facilitate design of further inhibitors of HIV-1 binding to CXCR4.

There is a need for antiviral agents which can block HIV-1 entry via CXCR4. Preferably, but not necessarily, such peptides would not 15 block the ability of CXCR4 to bind its natural ligand, SDF-1.

Ideally, selective inhibitors of HIV infection should comprise small molecule drugs. In contrast to other large protein-based therapeutics such as monoclonal antibodies, such small agents are advantageous since they are more likely to be non-immunogenic, orally administrable, and 20 amenable for chemical synthesis and modification.

There is further need for improved chemokine peptides useful as therapeutic agents which provide enhanced activity and/or stability over existing chemokine peptides.

Summary of the Invention

25 It is an object of the invention to provide antiviral synthetic peptides capable of inhibiting HIV-1 infection, by inhibiting HIV-1 mediated cytopathogenesis and cell fusion.

It is an object to provide a method of treating or inhibiting HIV-1 infection, by administration of the synthetic peptides.

It is an object of the invention to provide other synthetic chemokine peptides with enhanced properties.

The antiviral compounds of the present invention are in the form of peptides which possess anti-HIV activity. They inhibit HIV-1 entry 5 into HIV-1 infection susceptible cells via the CXC chemokine receptor 4.

In all embodiments, the peptide may optionally comprise an amino-terminal and/or carboxy-terminal protecting group.

According to one embodiment, the invention is a peptide of the formula

10 $X_1\text{-}A\text{-}B\text{-}C\text{-}D\text{-}X_2\text{-}E\text{-}F\text{-}G\text{-}X_3\text{-}L\text{-}X_4\text{-}J\text{-}K\text{-}M\text{-}N\text{-}P\text{-}Q\text{-}R\text{-}S\text{-}T\text{-}V\text{-}Ala\text{-}W\text{-}Y\text{-}X_5}$ (I)

wherein:

X_1 is from zero to eight amino acids,

X_2 is three amino acids,

X_3 is from zero to eight amino acids,

15 L is a linker comprising a covalent bond or chemical moiety,

X_4 is from zero to eight amino acids,

X_5 is from zero to eight amino acids,

A is Ile, Leu, Phe or Val,

B is Ser or Thr

20 C is Phe, Tyr, or Trp,

D is Arg, His or Lys,

E is Arg, His or Lys,

F is Phe, Tyr, Trp or Leu

G is Phe, Tyr, Trp or Leu

25 J is Ile, Leu, Phe or Val,

K is Arg, Lys or His,

M is Phe, Tyr or Trp

N is Ile, Leu, Phe or Val,

P is Asn, Asp, Glu or Gln

30 Q is Asn, Asp, Glu or Gln

R is Tyr, Trp or Phe,

S is Ile, Leu, Phe or Val,
T is Asn, Asp, Glu or Gln
V is Arg, Lys or His,
W is Ile, Leu, Phe or Val,
5 Y is Asn, Asp, Glu or Gln, and
said peptide optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

In preferred embodiments, A is Leu, B is Ser, C is Tyr, D is Arg, E is Arg, F is Phe, G is Phe, J is Leu, K is Lys, M is Trp, N is Ile, P is 10 Gln, Q is Glu, R is Tyr, S is Leu, T is Glu, V is Lys, W is Leu and/or Y is Asn.

In preferred embodiments, each of X_1 , X_3 , X_4 , and X_5 is from zero to six amino acids, preferably zero to four amino acids.

In the foregoing embodiments of the invention, it should be 15 understood that each amino acid of the segments X_1 , X_2 , X_3 , X_4 , and X_5 may comprise, independent of any other amino acid in the segment, any amino acid.

According to another preferred embodiment,

X_1 is
20 (i) zero amino acids, or
(ii) the segment $A^1-B^1-C^1-D^1$ or N-terminal truncation fragment thereof containing at least one amino acid, wherein:

25 A^1 is Arg, Lys or His,
 B^1 is Pro or N-methylalanine,
 C^1 is Ile, Leu, Phe or Val, and
 D^1 is Ser or Thr;

X_3 is
30 (i) zero amino acids, or

(ii) the segment A²-B²-C²-D²-Ala-E²-Ala-F², or C-terminal truncation fragment thereof containing at least one amino acid, wherein:

A² is Asn, Asp, Glu or Gln,

5

B² is Ser or Thr,

C² is Arg, Lys or His,

D² is Ile, Leu, Phe or Val,

E² is Arg, Lys or His,

F² is Asn, Asp, Glu or Gln;

10

X₄ is

(i) zero amino acids, or

(ii) the segment A³-B³-C³-D³, or N-terminal truncation fragment thereof containing at least one amino acid, wherein:

15

A³ is Ile, Leu, Phe or Val,

B³ is Asn, Asp, Glu or Gln,

C³ is Pro or N-methylalanine,

D³ is Arg, Lys or His; and

X₅ is zero amino acids.

20

According to another preferred embodiment, L is an amino acid sequence containing from 2 to 10 amino acids, more preferably from 2 to 6 amino acids, most preferably from 2 to 4 amino acids. In some embodiments of the invention, the amino acid sequence L comprises glycine or lysine amino acids.

25

In some embodiments, X₂ is Cys-Pro-Cys.

According to other embodiments,

A-B-C-D is Leu-Ser-Tyr-Arg (SEQ ID NO:11),

E-F-G is Arg-Phe-Phe

J-K-M-N-P-Q-R-S-T-V is Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys (SEQ ID NO:12), and

W-Y is Leu-Asn.

According to other embodiments,

5 the segment A¹-B¹-C¹-D¹ is Lys-Pro-Val-Ser (SEQ ID NO:1) or N-terminal truncation fragment thereof containing at least one amino acid;

10 the segment A²-B²-C²-D²-Ala-E²-Ala-F² is Glu-Ser-His-Val-Ala-Arg-Ala-Asn (SEQ ID NO:2), or C-

terminal truncation fragment thereof containing at least one amino acid; and

15 the segment A³-B³-C³-D³ is Ile-Asp-Pro-Lys (SEQ ID NO:3), or C-terminal truncation fragment thereof containing at least one amino acid.

15 A pharmaceutical composition comprises a pharmaceutically acceptable carrier and a peptide according to the invention.

A method of inhibiting entry of HIV-1 into CXCR4-expressing cells comprises contact the cells with a peptide according to the invention.

20 A method of inhibiting infection by HIV-1 comprises administering to an individual an effective amount of a peptide according to the invention.

25 According to another embodiment of the invention, a synthetic chemokine peptide is provided. The peptide comprises an N-terminal segment comprising a sequence of from 10 to 25 amino acids having at least 50% sequence identity with a first reference segment of a naturally occurring chemokine, said first reference segment being found in the N-terminal region of said naturally occurring chemokine. The peptide further comprises a C-terminal segment comprising a sequence of from 10 to 25 amino acids having at least 50% sequence identity with a second reference segment of the naturally occurring chemokine, said second first reference

segment being found in the C-terminal region of the naturally occurring chemokine. The N-terminal and C-terminal segments of the synthetic peptide are connected by a linker L as defined above. The linker links the C-terminus of the synthetic peptide N-terminal segment to the N-terminus 5 of the synthetic peptide C-terminal segment. Preferably, the degree of sequence identity between each segment of the synthetic peptide and the corresponding first or second reference sequence of the naturally occurring chemokine is at least about 70%, more preferably at least about 80%, most preferable about 90%. In preferred embodiments, the amino acid 10 sequence of the N-terminal segment differs, if at all, from the first reference segment of the naturally occurring chemokine only by conservative amino acid substitutions, and the amino acid sequence of the C-terminal segment differs, if at all, from the second reference segment of the naturally occurring chemokine only by conservative amino acid substitutions.

15 Other aspects and advantages of the present invention are described in the drawings and in the following detailed description of the preferred embodiments thereof.

Abbreviations and Short Forms

20 "CXCR4" means CXC chemokine receptor 4.
"HIV-1" means human immunodeficiency virus type 1.
"SDF-1" means stromal cell-derived factor-1.

Amino Acid Abbreviations

The nomenclature used to describe polypeptide compounds of the present invention follows the conventional practice wherein the 25 amino group is presented to the left and the carboxy group to the right of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino-and carboxy-terminal groups, although not specifically shown, will be understood to be in the

form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by a three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following schedule:

5	Alanine	Ala
	Cysteine	Cys
	Aspartic Acid	Asp
	Glutamic Acid	Glu
	Phenylalanine	Phe
10	Glycine	Gly
	Histidine	His
	Isoleucine	Ile
	Lysine	Lys
	Leucine	Leu
15	Methionine	Met
	Asparagine	Asn
	Proline	Pro
	Glutamine	Gln
	Arginine	Arg
20	Serine	Ser
	Threonine	Thr
	Valine	Val
	Tryptophan	Trp
	Tyrosine	Tyr

25 Definitions

The following definitions, of terms used throughout the specification, are intended as an aid to understanding the scope and practice of the present invention.

30 A "peptide" is a compound comprised of amino acid residues covalently linked by peptide bonds.

The expression "amino acid" as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids. **"Natural amino acid"** means any of the twenty primary, naturally occurring amino acids which typically form peptides, polypeptides, and 35 proteins. **"Synthetic amino acid"** means any other amino acid, regardless of whether it is prepared synthetically or derived from a natural source. As

used herein, "synthetic amino acid" also encompasses chemically modified amino acids, including but not limited to salts, derivatives (such as amides), and substitutions. Amino acids contained within the peptides of the present invention, and particularly at the carboxy- or amino-terminus, can be 5 modified by methylation, amidation, acetylation or substitution with other chemical groups which can change the peptide's circulating half life without adversely affecting their activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention, as long as anti-HIV activity is maintained.

10 Amino acids have the following general structure:



15

Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side 20 chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group. Peptides comprising a large number of amino acids are sometimes called "polypeptides". The amino acids of the peptides described herein and in the appended claims are understood to be either D or L amino acids with L amino acids being 25 preferred.

As used herein, "protected" with respect to a **terminal amino group** refers to a terminal amino group of a peptide, which terminal amino group is coupled with any of various amino-terminal protecting groups traditionally employed in peptide synthesis. Such protecting groups 30 include, for example, acyl protecting groups such as formyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl; aromatic urethane protecting groups such as benzyloxycarbonyl; and aliphatic urethane protecting

groups, for example, tert-butoxycarbonyl or adamantlyloxycarbonyl. See Gross and Mienhofer, eds., *The Peptides*, vol. 3, pp. 3-88 (Academic Press, New York, 1981) for suitable protecting groups.

As used herein, "**protected**" with respect to a **terminal carboxyl group** refers to a terminal carboxyl group of a peptide, which terminal carboxyl group is coupled with any of various carboxyl-terminal protecting groups. Such protecting groups include, for example, tert-butyl, benzyl or other acceptable groups linked to the terminal carboxyl group through an ester or ether bond.

By "**synthetic chemokine peptide**" is meant a peptide having an amino acid sequence, substantial portions of which are the same as or homologous to portions of the amino acid sequence of a naturally occurring chemokine.

By "**N-terminal segment**" or "**N-terminal portion**" is meant a part of a peptide or mature polypeptide which terminates in the N-terminal amino acid of the peptide or polypeptide.

By "**C-terminal segment**" or "**C-terminal portion**" is meant a part of a peptide or a mature polypeptide which terminates in the C-terminal amino acid or polypeptide..

By "**N-terminal truncation fragment**" with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the N-terminus thereof.

By "**C-terminal truncation fragment**" with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the C-terminus thereof.

Description of the Figures

Figure 1 is a bar graph of the percent inhibition of cell fusion of the peptides of the invention (SEQ ID NO:4-7) compared to peptides corresponding to the SDF-1 N-terminus (SEQ ID NO:8, 10) in an HIV-1 gp120-CXCR4-mediated cell fusion assay.

Detailed Description of the Invention

According to the present invention, synthetic peptides have been designed based upon a previously unknown model of the CXCR4-SDF-1 complex. These peptides inhibit HIV-1 viral entry via CXCR4 in a concentration dependent manner. The peptides inhibit infectivity of HIV-1. Hence, the peptides are useful as therapeutics for reducing ongoing viral infection, or as prophylactics for inhibiting viral infection, particularly infection of CXCR4 + cells.

Using a molecular modeling approach, a proposed structure was constructed for the transmembrane helices of CXCR4. This model indicates that the N-terminal region of CXCR4 plays a critical role in recognizing SDF-1 and contributes the most in terms of ligand binding energy. In addition to the N-terminus in both receptor and ligand, the role of other regions such as ECL2 and ECL3 of CXCR4 and the C-terminal helix of SDF-1 was also revealed in the structural model. This model permitted, for the first time, the identification of putative binding sites in SDF-1, and the design of novel peptides comprising both N- and C-termini of SDF-1. The peptides are inhibitors of CXCR4 mediated HIV-1 fusion. They inhibit HIV-1 transmission to uninfected cells.

The antiviral activity of any SDF1-derived peptide of the invention may be measured by a convenient *in vitro* cell-cell fusion assay. An HIV-1 gp120-CXCR4 mediated cell-cell fusion assay is used to test the effect of peptides on HIV-1 virus entry via CXCR4. For the assay, HIV-1 Env proteins and T7 RNA polymerase were introduced into effector 293 cells by infection with recombinant vaccinia virus at a multiplicity of infection

of 10 for 2 hours. QT6 target cells were transfected in 6-well plates with plasmids encoding CD4, CXCR4 and luciferase under control of T7 promoter, using the calcium phosphate precipitation method. The effector and target cells were then subjected to fusion conditions in the presence 5 of peptide. Following fusion, the cells were lysed in reporter lysis buffer and assayed for luciferase activity using commercially available reagents.

An HIV-induced syncytia assay may also be utilized to test the antiviral activity of the SDF1-derived peptides of the invention. Accordingly, uninfected CD4+ cells (such as Molt or CEM cells, for 10 example) are cultured in the presence of chronically HIV-infected cells and peptide. The conditions for HIV-induced syncytia formation assays are well-known to those skilled in the art. See e.g. U. S. Pat. 5,464,933, incorporated herein by reference. The culture is examined for the presence 15 of multinucleated giant cells, which are indicative of cell fusion and syncytia formation.

In addition to the cell-cell fusion assay, the binding of the peptides of the invention to CXCR4 was also characterized by a fluorescence-activated cell sorter (FACS) analysis. 293 cells transfected with CXCR4 and a FITC conjugated antibody against CXCR4, 12D5 20 (Endres *et al.*, *Cell* 87:745-756, (1996)) were used for the assay. Another FITC conjugated antibody against CCR5, 12D1 (Doranz *et al.*, *Cell* 85:1149-58, (1996)) was used as a negative control. FITC-12D1 against CCR5 showed no binding to 293 cells transfected with CXCR4, whereas 25 FITC-12D5 against CXCR4 exhibited strong binding. Peptides of the present invention significantly blocked the binding of 12D5 to CXCR4, whereas a control peptide analog of MIP-1 β had no effect. These results provide further evidence for the involvement in CXCR4 binding of both N- and C-termini of SDF-1.

Each SDF1-derived peptide of the invention comprises a first 30 segment which mimics the N-terminal binding site of SDF-1 for CXCR4 and a second segment which mimics the C-terminal binding site of SDF-1 for

CXCR4. The segments are joined by a linker. The peptides possess enhanced receptor binding and inhibition of HIV-1 entry. The peptides of the invention are characterized by enhanced activity over separate peptides derived only from the N-terminal region of SDF-1, or derived only 5 from the C-terminal region of SDF-1.

The N-terminal segment of the peptides comprise a core segment A-B-C-D-X₂-E-F-G substantially corresponding to amino acids 5-14 of the native SDF-1 native amino acid sequence. Amino acids A, B, C, and D represent the corresponding native amino acids Leu, Ser, Tyr and 10 Arg, respectively, or conservative substitutions thereof. X₂ is any three amino acids, preferably the native sequence Cys-Pro-Cys. Amino acids E, F and G represent the corresponding native amino acids Arg, Phe and Phe, respectively, or conservative substitutions thereof. Conservative amino acid substitutions typically include substitutions within the following groups: 15 glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; phenylalanine and tyrosine.

The core segment within the larger N-terminal segment may be flanked by a segment X₁ containing up to eight additional amino acids 20 upstream (i.e., in the N-terminal direction) of the core segment, and a segment X₃ containing up to eight additional amino acids downstream (i.e., in the C-terminal direction) of the core segment. Preferably, X₁ is a segment of four amino acids A¹-B¹-C¹-D¹, or N-terminal truncation fragment thereof) corresponding to amino acids 1-4 of the native SDF-1 native amino 25 acid sequence. Amino acids A¹, B¹, C¹ and D¹ represent the corresponding native amino acids Lys, Pro, Val and Ser, respectively, or conservative substitutions thereof. Preferably, X₃ is a segment of eight amino acids A²-B²-C²-D²-Ala-E²-Ala-F² (or C-terminal truncation fragment thereof) corresponding to amino acids 15-22 of the native SDF-1 native 30 amino acid sequence. Amino acids A², B², C², D², E² and F² represent the corresponding native amino acids Glu, Ser, His, Val, Arg and Asn,

respectively, or conservative substitutions thereof. The core segment A-B-C-D-X₂-E-F-G and the optional flanking segments X₁ and X₃ form the complete N-terminal segment of the peptides of the invention.

The C-terminal segment of the present peptides comprises
5 a core segment J-K-M-N-P-Q-R-S-T-V-Ala-W-Y corresponding to amino acids 55-67 of the native SDF-1 native amino acid sequence. Amino acids J, K, M, N, P, Q, R, S, T, V, W and Y represent the corresponding native amino acids Leu, Lys, Trp, Ile, Gly, Glu, Tyr, Leu, Glu, Lys, Leu and Asn, respectively, or conservative substitutions thereof.

10 The core segment within the larger C-terminal segment may be flanked by a segment X₄ containing up to eight additional amino acids upstream of the core segment, and a segment X₅ containing up to eight additional amino acids downstream of the core segment. Preferably, X₄ is a segment of four amino acids A³-B³-C³-D³ (or N-terminal truncation
15 fragment thereof) corresponding to amino acids 51-54 of the native SDF-1 amino acid sequence. Amino acids A³, B³, C³ and D³ represent the corresponding native amino acids Ile, Asp, Pro and Lys, respectively, or conservative substitutions thereof. Preferably, X₅ is zero amino acids. The core segment J-K-M-N-P-Q-R-S-T-V-Ala-W-Y and the optional flanking
20 segments X₄ and X₅ form the complete C-terminal segment of the peptides of the invention.

In the broadest embodiment of the SDF1 peptides of the invention, flanking sequences X₁, X₃, X₄, X₅ may comprise any amino acid. However, these flanking segments are preferably derived from the native
25 SFD-1 sequence, and thus duplicate the native amino acid sequence of SFD-1, or comprise conservative amino acid substitutions of one or more native amino acids.

The linker connecting the SDF-1 N-terminal and C-terminal peptide segments forming the peptides of the invention may comprise a
30 covalent bond or a chemical moiety. The linker may comprise any chemical group which is compatible with the peptide segments being linked

and which does not adversely affect the binding of the peptide to the CXCR4 receptor. The linker is preferably flexible, and maintains the relative spatial geometry of the two segments of the peptide. Preferably, the spacer is a segment comprising a series of amino acids, most 5 preferably from 2 to ten amino acids, most preferably from 2 to six amino acids. According to one preferred embodiment of the invention, the linker comprises glycine or lysine amino acids, such as the segment Gly-Gly-Gly-Gly or Lys-Lys-Lys-Lys. Glycine residues are particularly preferred as they maintain the relative spatial geometry of the N-terminal and C-terminal 10 SDF-1 analogs, and provide flexibility to this bridge.

According to one embodiment of the invention, the linker is a peptide bond. Hence, the connection between the SDF-1 N-terminal and C-terminal peptide segments in this embodiment is a peptide bond joining the C-terminal amino acid residue of the N-terminal peptide segment and 15 the N-terminal amino acid residue of the C-terminal peptide segment.

Preferred SDF1-derived peptides according to the present invention inhibit, at a concentration of no more than 25 μ M, greater than 50% (preferably greater than 75%) of the binding of (i) gp120-expressing 293 cells transfected to express T7 RNA polymerase and (ii) human CD4- 20 expressing QT6 cells transfected to express CD4 and the CXCR4. Such a cell-cell binding assay is described in Example 1, below.

According to another embodiment of the invention, a similar strategy is employed to prepare synthetic peptides based upon the amino acid sequences of other chemokines. For a review of chemokines and 25 their receptors, and their classification, see Premack & Schall, *Nature Medicine* 2(11):1174-1178 (1996), the entire disclosure of which is incorporated herein by reference. The N-terminal region of a chemokine is the principal site by which the chemokine interacts with its receptor, and is therefore primarily responsible for the chemokine's biological activity. It 30 is believed that the C-terminal region of the molecule plays a role in recruiting the chemokine to the cell surface where the chemokine receptor

is located. The C-terminal region also plays a role in stabilizing the chemokine once bound to the receptor. Stabilization includes prevention of enzyme hydrolysis of the chemokine, so that the chemokine maintains its signaling function once bound to the receptor.

5 While chemokine synthetic peptides have been prepared, they are typically based upon the chemokine N-terminal amino acid sequence to mimic the receptor binding site on the chemokine. Such peptides therefor omit the beneficial recruitment and stabilization functions of the chemokine C-terminal domain.

10 According to the present invention, chemokine synthetic peptides are provided. Each such synthetic peptide comprises a first (N-terminal) segment which mimics the N-terminal region of the corresponding naturally occurring full-length chemokine polypeptide. The N-terminal segment of the synthetic chemokine peptide contains or mimics the binding 15 site for the corresponding chemokine receptor.

Each synthetic chemokine peptide further comprises a second (C-terminal) segment which mimics the C-terminal region of the corresponding naturally occurring full-length chemokine polypeptide. The C-terminal segment is available to perform the recruitment and stabilization 20 functions of the C-terminal region of the full-length chemokine polypeptide.

The result of this N-terminal/C-terminal segment construction is a synthetic molecule incorporating the major functional characteristics of the corresponding naturally occurring chemokine. It is expected, as demonstrated in the case of the synthetic SDF-1 peptides described herein, 25 that other synthetic chemokine peptides based upon this construction will have enhanced biological activity over peptide analogs modeled from the native N-terminal region alone.

The N-terminal segment of the inventive peptides comprises a sequence of from about 10 to about 25, more preferably from about 10 30 to about 20, most preferably from about 10 to about 15, amino acids from a reference segment of approximately the same length forming the N-

terminal portion of the corresponding naturally occurring chemokine. Similarly, the C-terminal segment of the inventive peptides comprises a sequence of from about 10 to about 25, more preferably from about 10 to about 20, most preferably from about 10 to about 15, amino acids from a 5 reference segment of approximately the same length forming the C-terminal portion of the corresponding naturally occurring chemokine. The amino acid sequence of the segments is identical to the corresponding chemokine native amino sequence portions, or one or more positions may be substituted with other amino acids. The substitutions preferably 10 comprise conservative amino acid substitutions. According to one embodiment of the invention, each segment has at least 50%, preferably at least 70%, more preferably at least 80%, most preferably at least 90%, sequence identity with the corresponding native chemokine portion of the same length. By "sequence identity" is meant the same amino acids in the 15 same relative positions. The segments are connected by a linker as described above.

The synthetic chemokine peptides may be synthesized utilizing the known amino acid sequences of the various known chemokines. The following is a partial list of human chemokines and the 20 corresponding GenBank accession numbers for GenBank records providing the nucleotide (DNA or mRNA) and encoded amino acid sequences. Each GenBank record is incorporated herein by reference. "NID" is the National Center for Biotechnology and Information sequence identifier. By "cds" is meant coding sequence.

25	Chemokines GenBank Record	Accession No.	NID
	Human eotaxin precursor mRNA, complete cds	U46573	g1280140
	Human monocyte chemoattractant protein-4 precursor (MCP-4) mRNA, complete cds	U46767	g1732122
30	Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds	L36034	g1220363

	Human pre-B cell stimulating factor homologue (SDF1b) mRNA, complete cds	L36033	g1220365
	Human mRNA for EBI1-ligand chemokine, complete cds	AB000887	g2189952
5	Human DNA for SCM-1beta precursor, complete cds	D63789	g1754608
	Human DNA for SCM-1alpha precursor, complete cds	D63790	g1754610
	Human mRNA for CC chemokine LARC precursor, complete NID	D86955	G1871138
10	Human macrophage-derived chemokine precursor (MDC) mRNA, complete cds	U83171	g1931580
	Human CC chemokine STCP-1 mRNA, complete cds	U83239	g2062424
15	Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds	U84487	g1888522
	Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete cds	U85767	g1916249
	Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete cds	U85768	g1916251
20	Human chemokine (TECK) mRNA, complete cds	U86358	g2388626
	Human beta chemokine Exodus-2 mRNA, complete cds	U88320	g2196919
	Human beta chemokine Exodus-3 mRNA, complete cds	U88321	g2196921
25	Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds	U91835	g1899258
	Human mRNA for chemokine, complete cds	D43767	g1536878
	Human mRNA for eotaxin, complete cds	D49372	g1552240
	Human eotaxin precursor gene, complete cds	U46572	g2088508
30	Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA, complete cds	U77035	g1790924
	Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA, complete cds	U77180	g1791002
35	Human line-1 reverse transcriptase gene, partial cds, and granulocyte chemotactic protein-2 (GCP-2) gene, complete cds	U83303	g1916228
	Human netrin-2 like protein (NTN2L) gene, complete cds	U86758	g2052392

	Human Duffy blood group antigen (Fya-b+) mRNA, complete cds	U01839	g425267
	Human herpesvirus 6 serotype B putative major immediate-early genes	U92288	g2769711
5	Human herpesvirus-6 (HIV-6) u1102, variant A, complete virion genome	X83413	g853961
	Kaposi's sarcoma-associated herpesvirus BCK gene, complete cds	U83351	g1778605
	Human C6 beta-chemokine mRNA, complete cds	U67128	g4097705
10	Human chemokine alpha 3 (CKA-3) mRNA, complete cds	U81234	g4098960
	Human monocyte chemotactic protein-4 precursor (MCP-4) mRNA, complete cds	U59808	g4097420
	Human chemokine (hmrp-2a) mRNA, complete cds	U58913	g4204907
15	Human chemokine (hmrp-2b) mRNA, complete cds	U58914	g4204909
	H.sapiens mRNA for CC-chemokine.	Z69291	g1181148
	H.sapiens mRNA for CC-chemokine, eotaxin variant (clone 34).	Z75669	g1531980
20	H.sapiens mRNA for CC-chemokine, eotaxin variant (clone 53).	Z75668	g1531982
	H.sapiens gene for chemokine HCC-1.	Z49269	g1004266
	H.sapiens mRNA for chemokine HCC-1.	Z49270	g1004268
	H.sapiens Humig mRNA. X72755	S60728	g311375
25	H.sapiens NC28 mRNA for monocyte chemoattractant protein (MCP-3).	X71087	g288396
	H.sapiens mRNA for ATAC protein.	X86474	g895846
	Human eotaxin precursor mRNA, complete cds.	U46573	g1280140
	Human monocyte chemoattractant protein-4 precursor (MCP-4) mRNA, complete cds.	U46767	g1732122
30	Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds.	L36034	g1220363
	Human pre-B cell stimulating factor homologue (SDF1b) mRNA, complete cds.	L36033	g1220365
35	pro-inflammatory cytokine {promoter} [human, placenta, Genomic, 1016 nt].	S64885	g408870
	Duffy [human, Caucasian individual AZ, Fy(a-b-) phenotype, erythrocytes, Genomic Mutant, 88 nt].	S79269	g1086935
	Homo sapiens mRNA for CC chemokine, complete cds.	AB000221	g2289718
40	Human mRNA for EBI1-ligand chemokine, complete cds.	AB000887	g2189952
	Homo sapiens mRNA for SLC, complete cds.	AB002409	g2335034
	Homo sapiens mRNA for chemokine LEC precursor, complete cds.	AB007454	g2723285
45	Homo sapiens beta chemokine mRNA, complete cds.	AF001979	g2624924
	Homo sapiens Angie mRNA, complete cds.	AF029894	g3169813

	Homo sapiens MIP-1 delta mRNA, complete cds.	AF031587	g2739163
	Homo sapiens monocyte chemoattractant protein 3 (MCP3) mRNA, partial cds.	AF043338	g2905625
5	Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a) mRNA, partial cds.	AF043339	g2905627
	Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a) mRNA, partial cds.	AF043340	g2905629
	Homo sapiens RANTES precursor, mRNA, complete cds.	AF043341	g2905631
10	Homo sapiens B lymphocyte chemoattractant BLC mRNA, complete cds.	AF044197	g2911375
	Homo sapiens monotactin-1 mRNA, complete cds.	AF055467	g3395775
	Human DNA for SCM-1beta precursor, complete cds.	D63789	g1754608
15	Human DNA for SCM-1alpha precursor, complete cds.	D63790	g1754610
	Human mRNA for CC chemokine LARC precursor, complete cds.	D86955	g1871138
	Homo sapiens CC chemokine DC-CK-1/PARC/MIP-4 gene, exon 1.	AF082212	g3426358
20	Homo sapiens CC chemokine DC-CK-1/PARC/MIP-4 gene, exon 2.	AF082213	g3426359
	Homo sapiens CC chemokine DC-CK-1/PARC/MIP-4 gene, exon 3 and complete cds.	AF082214	g3426360
25	Homo sapiens mRNA for alternative activated macrophage specific CC chemokine 1.	Y13710	g2326515
	H.sapiens mRNA for chemokine CC-2 and CC-1.	Z70292	g1296608
	Homo sapiens cDNA for a CXC chemokine.	AJ002211	g2832410
	H.sapiens MCP-2 gene.	X99886	g1905800
30	H.sapiens MCP-3 gene for monocyte chemotactic protein-3.	X72309	g515869
	H.sapiens mRNA for monocyte chemoattractant protein 4.	X98306	g2689216
	Homo sapiens chemokine exodus-1 mRNA, complete cds.	U64197	g1778716
35	Human macrophage-derived chemokine precursor (MDC) mRNA, complete cds.	U83171	g1931580
	Human CC chemokine STCP-1 mRNA, complete cds.	U83239	g2062424
40	Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds.	U84487	g1888522
	Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete cds.	U85767	g1916249
	Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete cds.	U85768	g1916251
45	Human chemokine (TECK) mRNA, complete cds.	U86358	g2388626
	Human beta chemokine Exodus-2 mRNA, complete cds.	U88320	g2196919
	Human beta chemokine Exodus-3 mRNA, complete cds.	U88321	g2196921
50	Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete cds.	U91746	g2581780
	Human CX3C chemokine precursor, mRNA,	U91835	g1899258

	alternatively spliced, complete cds.		
	Homo sapiens Chromosome 16 BAC clone CIT987SK-A-152E5, complete sequence.	AC004382	g3252819
5	Human mRNA for chemokine, complete cds.	D43767	g1536878
	Human mRNA for eotaxin, complete cds.	D49372	g1552240
	human mRNA for SCM-1 (single cysteine motif-1), complete cds.	D43768	g927650
10	Homo sapiens gene for CC chemokine PARC precursor, complete cds.	AB012113	g3869137
	Homo sapiens putative alpha chemokine (H174) mRNA, complete cds.	AF002985	g2580585
	Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.	AF030514	g3219692
15	Homo sapiens putative small inducible subfamily B- type cytokine (SCYB9B) gene, partial cds.	AF053972	g3746491
	Homo sapiens CC chemokine gene cluster, complete sequence.	AF088219	g3719360
	Homo sapiens mRNA for monocyte chemotactic protein-3 (MCP-3).	X72308 S57464	g3928270
20	Human eotaxin precursor gene, complete cds.	U46572	g2088508
	Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA, complete cds.	U77035	g1790924
	Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA, complete cds.	U77180	g1791002
25	Human line-1 reverse transcriptase gene, partial cds, and granulocyte chemotactic protein-2 (GCP-2) gene, complete cds.	U83303	g1916228
	Human netrin-2 like protein (NTN2L) gene, complete cds.	U86758	g2052392
30	Human Duffy blood group antigen (Fya-b+) mRNA, complete cds.	U01839	g425267
	HIV-1 patient AB28 from Argentina, envelope glycoprotein (env) gene, partial cds.	AF001428	g2105008
35	HIV-1 patient CD65 from Argentina, envelope glycoprotein (env) gene, partial cds.	AF001429	g2105010
	HIV-1 patient CS93 from Argentina, envelope glycoprotein (env) gene, partial cds.	AF001430	g2105012
	HIV-1 patient FS3 from Argentina, envelope glycoprotein (env) gene, partial cds.	AF001431	g2105014
40	HIV-1 child B136 JA3613 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023305	g3642779
	HIV-1 child B136 J6366 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023306	g3642781
45	HIV-1 child B136 J57 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023307	g3642788
	HIV-1 child B136 J108 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023308	g3642790
	HIV-1 child B136 J130 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023309	g3642793
50	HIV-1 child B145 J3284 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023310	g3642795
	HIV-1 child B145 J5508 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023311	g3642797

	HIV-1 child B145 J34 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023312	g3642800
5	HIV-1 child B145 J132 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023313	g3642802
	HIV-1 child B193 JA4200 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023314	g3642804
	HIV-1 child B193 J6195 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023315	g3642806
10	HIV-1 child B196 J4757 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023316	g3642808
	HIV-1 child B196 J10001 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023317	g3642810
	HIV-1 child B199 J4758 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023318	g3642812
15	HIV-1 child B199 J5513 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023319	g3642821
	HIV-1 child B199 J27 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023320	g3642823
20	HIV-1 child B204 J4448 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023321	g3642825
	HIV-1 child B204 J4755 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023322	g3642829
	HIV-1 child B204 J5233 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023323	g3642831
25	HIV-1 child B204 J10003 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023324	g3642833
	HIV-1 child B224 J5151 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023325	g3642838
	HIV-1 child B224 J6363 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023326	g3642840
30	HIV-1 child B224 J58 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023327	g3642844
	HIV-1 child B224 J203 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023328	g3642846
35	HIV-1 child B32 J4070 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023329	g3642848
	HIV-1 child B32 J5988 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023330	g3642850
40	HIV-1 child B32 J190 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023331	g3642852
	HIV-1 child B3 J4443 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023332	g3642860
	HIV-1 child B3 J6088 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023333	g3642863
45	HIV-1 child B3 J10005 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023334	g3642865
	HIV-1 child B3 J62 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023335	g3642868
	HIV-1 child B3 J176 isolate from Italy, envelope glycoprotein V3 region (env) gene, partial cds.	AF023336	g3642870
50	Gallid herpesvirus 1 CXC chemokine vIL8 mRNA, complete cds.	AF065430	g3873222
	Human herpesvirus 6 serotype B putative major	U92288	g2769711

	immediate-early genes.		
	Human herpesvirus-6 (HHV-6) U1102, variant A, complete virion genome.	X83413	g853961
5	HIV-1 patient A isolate J2195 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76078	g1698913
10	HIV-1 patient A isolate J4052 from Sweden envelope glycoprotein V3 region (env) gene, partial cds.	U76079	g1698915
15	HIV-1 patient B isolate J562 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76080	g1698917
20	HIV-1 patient B isolate J975 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76081	g1698919
25	HIV-1 patient C isolate J669 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76082	g1698921
30	HIV-1 patient C isolate J1629 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76083	g1698923
35	HIV-1 patient D isolate J1874 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76084	g1698925
40	HIV-1 patient D isolate J2337 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76085	g1698927
45	HIV-1 patient E isolate J2090 from Sweden, envelope glycoprotein V3 region (env) gene, partial cds.	U76086	g1698929
50	Kaposi's sarcoma-associated herpesvirus BCK gene, complete cds.	U83351	g1778605
	qp81e03.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE:1929436 3' similar to TR:O15444 O15444 CHEMOKINE. ;, mRNA sequence.	AI313153	g4018758
	qx07c01.x1 NCI_CGAP_Lym12 Homo sapiens cDNA clone IMAGE:2000640 3' similar to TR:O00585 O00585 BETA CHEMOKINE EXODUS-2. ;, mRNA sequence.	AI223954	-
	Homo sapiens CC chemokine LCC-1 precursor, gene, complete cds.	AF039954	g4039073
	Homo sapiens liver CC chemokine-1 precursor (SCYA16) mRNA, complete cds.	AF039955	g4039075
	Human C6 beta-chemokine mRNA, complete cds.	U67128	g4097705
	Human chemokine alpha 3 (CKA-3) mRNA, complete cds.	U81234	g4098960
	Homo sapiens CXC chemokine BRAK mRNA, complete cds.	AF073957	g4140393
	Human monocyte chemotactic protein-4 precursor (MCP-4) mRNA, complete cds.	U59808	g4097420
	Homo sapiens putative small inducible subfamily B-type cytokine (SCYB11) gene, partial cds.	AF053972	g3746491
	Human chemokine (hmrp-2a) mRNA, complete cds.	U58913	g4204907
	Human chemokine (hmrp-2b) mRNA, complete cds.	U58914	g4204909

	Homo sapiens gene for CC chemokine LEC, complete cds.	AB018249	g4033626
	Homo sapiens gene encoding EBI1-ligand chemokine.	AJ223410	g4128050
5	H.sapiens mRNA for CC-chemokine.	Z77650	g4128126
	Homo sapiens slc gene, exons 1 to 4.	AJ005654	g4128128
	H.sapiens mRNA for CC-chemokine (sequence variant).	Z77651	g4128134
10	Homo sapiens mRNA for CC-chemokine MCP-4.	AJ001634	g4138019
	Homo sapiens mRNA for chemokine IP-9.	Y15220	g4225953
	functional macrophage inflammatory protein vmip-i homolog [Kaposi's sarcoma-associated herpesvirus]	U75698	g1718266
	macrophage inflammatory protein vmip-ii homolog [Kaposi's sarcoma-associated herpesvirus]	U75698	g1718264
15	vmip-i, functional macrophage inflammatory protein 1-alpha homolog [Kaposi's sarcoma-associated herpesvirus]	U93872	g2246546
	vmip-ii, macrophage inflammatory protein 1-alpha homolog [Kaposi's sarcoma-associated herpesvirus]	U93872	g2246517
20	vmip-1a [Kaposi's sarcoma-associated herpesvirus]	U74585	g1658273
	vmip-1b [Kaposi's sarcoma-associated herpesvirus]	U67775	g1562496

The peptides of the invention are optionally protected at the N-terminus and C-terminus with appropriate amino-terminal and/or carboxy terminal protecting groups, as described above. Where the peptide termini are unprotected, it is understood that the peptide N-terminus comprises an amino group (-NH₂) and that the peptide C-terminus comprises a carboxyl (-COOH) group.

The peptides of the invention may be recombinant peptides, natural peptides, or synthetic peptides. They may also be chemically synthesized, using, for example, solid phase synthesis methods.

In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which the constituent amino acids are added to the growing peptide chain in the desired sequence. The use of various N-protecting groups, e.g., the carbobenzyloxy group or the t-butyloxycarbonyl group, various coupling reagents (e.g., dicyclohexylcarbodiimide or carbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-

succinimide, and the various cleavage reagents, e.g., trifluoroacetic acid (TEA), HCl in dioxane, boron tris-(trifluoracetate) and cyanogen bromide, and reaction in solution with isolation and purification of intermediates is well-known classical peptide methodology. The preferred peptide synthesis 5 method follows conventional Merrifield solid-phase procedures. See Merrifield, *J. Amer. Chem. Soc.* 85:2149-54 (1963) and *Science* 50:178-85 (1965). Additional information about the solid phase synthesis procedure can be had by reference to the treatise by Steward and Young (*Solid 10 Phase Peptide Synthesis*, W.H. Freeman & Co., San Francisco, 1969, and the review chapter by Merrifield in *Advances in Enzymology* 32:221-296, F.F. Nold, Ed., Interscience Publishers, New York, 1969; and Erickson and Merrifield, *The Proteins* 2:255 et seq. (ea. Neurath and Hill), Academic Press, New York, 1976. The synthesis of peptides by solution methods is described in Neurath *et al.*, eds. (*The Proteins*, Vol. II, 3d Ed., Academic 15 Press, NY (1976)).




Crude peptides may be purified using preparative high performance liquid chromatography. The amino terminus may be blocked according, for example, to the methods described by Yang *et al.* (*FEBS Lett.* 272:61-64 (1990)).

20 Peptide synthesis includes both manual and automated techniques employing commercially available peptide synthesizers. The peptides of the invention may be prepared by chemical synthesis and biological activity can be tested using the methods disclosed herein.

25 The peptides of the invention may be synthesized in a manner such that one or more of the bonds linking amino acid residues are non-peptide bonds. These non-peptide bonds may be formed by chemical reactions well known to those skilled in the art. In yet another embodiment of the invention, peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino 30 and/or carboxy termini, such that, for example, the stability, bio-availability, and/or inhibitory activity of the peptides is enhanced. For example,

hydrophobic groups such as carbobenzoyl, dansyl, or t-butyloxycarbonyl groups, may be added to the peptides' amino terminus. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino terminus. Additionally, the hydrophobic group, t-5 butyloxycarbonyl, or an amido group, may be added to the peptides' carboxy terminus.

The peptides may be labeled, for further use as biomedical reagents or clinical diagnostic reagents. For example, a peptide of the invention can be conjugated with a fluorescent reagent, such as a 10 fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), or other fluorescent. The fluorescent reagent may be coupled to the peptide through the peptide N-terminus or free amine side chains by any one of the following chemistries, where R is the fluorescent reagent:



Alternatively, the peptide may be radiolabeled by peptide radiolabeling 15 techniques well-known to those skilled in the art.

Further, the peptides of the invention may be synthesized such that their stearic configuration is altered. For example, the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer. Still further, at least one of the amino acid 20 residues of the peptide may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or inhibitory action of the peptides of the invention.

Alternatively, the peptides may be prepared utilizing recombinant DNA technology, which comprises combining a nucleic acid encoding the peptide thereof in a suitable vector, inserting the resulting vector into a suitable host cell, recovering the peptide produced by the 5 resulting host cell, and purifying the polypeptide recovered. The techniques of recombinant DNA technology are known to those of ordinary skill in the art. General methods for the cloning and expression of recombinant molecules are described in Maniatis (*Molecular Cloning*, Cold Spring Harbor Laboratories, 1982), and in Sambrook (*Molecular Cloning*, 10 Cold Spring Harbor Laboratories, Second Ed., 1989), and in Ausubel (*Current Protocols in Molecular Biology*, Wiley and Sons, 1987), which are incorporated by reference. The complete cDNA of human SDF-1 is reported, for example, under GenBank accession number U16752, incorporated herein by reference. From this nucleic acid sequence, 15 synthetic genes encoding SDF-1-derived peptides may be synthesized directly on a DNA synthesizer, or may be synthesized as complementary oligonucleotides which are ligated together to form the synthetic gene. References to GenBank records for other chemokines are provided above.

The nucleic acids encoding the synthetic chemokine peptides 20 may be operatively linked to one or more regulatory regions. Regulatory regions include promoters, polyadenylation signals, translation initiation signals (Kozak regions), termination codons, peptide cleavage sites, and enhancers. The regulatory sequences used must be functional within the cells of the vertebrate to be immunized. Selection of the appropriate 25 regulatory region or regions is a routine matter, within the level of ordinary skill in the art.

Promoters that may be used in the present invention include both constitutive promoters and regulated (inducible) promoters. The promoters may be prokaryotic or eukaryotic depending on the host. Among 30 the prokaryotic (including bacteriophage) promoters useful for practice of this invention are lacI, lacZ, T3, T7, lambda Pr' Pl' and trp promoters.

Among the eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor VI11), 5 tissue-specific promoters (e.g. actin promoter in smooth muscle cells), promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus immediate-early, retroviral LTR, metallothionein, SV40, E1a, and MLP promoters. Tetracycline-regulated transcriptional 10 modulators and CMV promoters are described in WO 96/01313, US 5,168,062 and 5,385,839, the entire disclosures of which are incorporated herein by reference.

15 Examples of polyadenylation signals that can be used in the present invention include but are not limited to SV40 polyadenylation signals and LTR polyadenylation signals.

The peptides of the invention are prepared by either chemical synthesis or recombinant DNA technology may then be assayed for 20 biological activity according to the assay methods described herein.

In some embodiments, the peptides of the present invention 25 may be used in the form of a pharmaceutically acceptable salt.

Suitable acids which are capable of forming salts with the peptides include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.

Suitable bases capable of forming salts with the peptides 30 include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl

amine, dimethyl amine and the like) and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine and the like).

The present invention provides methods for treating HIV-1 infection by inhibiting viral entry into cells expressing the CXCR4 receptor.

5 Such CXCR4-expressing cells include, for example, T-cells. Accordingly, one or more SDF-1 peptides according to the invention is administered to a patient in need of such treatment. A therapeutically effective amount of the drug may be administered as a composition in combination with a pharmaceutically carrier.

10 Pharmaceutically acceptable carriers include physiologically tolerable or acceptable diluents, excipients, solvents, adjuvants, or vehicles, for parenteral injection, for intranasal or sublingual delivery, for oral administration, for rectal or topical administration or the like. The compositions are preferably sterile and nonpyrogenic. Examples of
15 suitable carriers include but are not limited to water, saline, dextrose, mannitol, lactose, or other sugars, lecithin, albumin, sodium glutamate, cysteine hydrochloride, ethanol, polyols (propyleneglycol, ethylene, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, ethoxylated isosteraryl
20 alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

The pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, 25 emulsifying agents, pH buffering agents, antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol, sorbic acid, and the like). If desired, absorption enhancing or delaying agents (such as liposomes, aluminum monostearate, or gelatin) may be used. The compositions can be prepared in conventional forms, either as liquid solutions or
30 suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Compositions containing the SDF-1 peptides may be administered by any convenient route which will result in delivery to the site of infection of CXCR4-expressing cells by HIV-1, in an amount effective for inhibiting that infection from proceeding. Modes of administration include, 5 for example, orally, rectally, parenterally (intravenously, intramuscularly, intraarterially, or subcutaneously); intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray or aerosol.

The pharmaceutical compositions are most effectively 10 administered parenterally, preferably intravenously or subcutaneously. For intravenous administration, they may be dissolved in any appropriate intravenous delivery vehicle containing physiologically compatible substances, such as sodium chloride, glycine, and the like, having a buffered pH compatible with physiologic conditions. Such intravenous 15 delivery vehicles are known to those skilled in the art. In a preferred embodiment, the vehicle is a sterile saline solution. If the peptides are sufficiently small, other preferred routes of administration are intranasal, sublingual, and the like. Intravenous or subcutaneous administration may comprise, for example, injection or infusion.

20 The SDF1-derived peptides according to the invention can be administered in any circumstance in which inhibition of HIV infection is desired. The peptides of the invention may be used for treatment of subjects as a preventative measure to avoid HIV infection, or as a therapeutic to treat patients already infected with HIV. The viruses whose 25 transmission may be inhibited by the peptides of the invention include strains of HIV-1, but is most useful for those strains which gain entry via the CXCR4, such as T-tropic and dual-tropic strains. T-tropic strains utilize CXCR4 for entry, while dual-tropic strains utilize CXCR4 or CCR5 (Simmons *et al.*, *J. Virol.* 70:8355-60, 1996). The peptides of the invention 30 may be used prophylactically in uninfected individuals after exposed to an HIV virus. Examples of such uses include in the prevention of viral

transmission from mother to infant, and following accidents in healthcare wherein workers may become exposed to HIV-contaminated blood, syringes and the like. The peptides may be administered to other individuals at risk of contracting HIV, such as homosexuals, prostitutes and 5 intravenous drug users.

The SDF1-derived peptides may be administered alone or in combination with other peptides or other anti-HIV pharmaceutical agents. The effective amount and method of administration will vary based upon the sex, age, weight and disease stage of the patient, whether the 10 administration is therapeutic or prophylactic, and other factors apparent to those skilled in the art. Based upon the studies described herein, a suitable dosage of peptide is a dosage which will attain a tissue concentration of from about 1 to about 100 μ M, more preferably from about 10 to about 50 μ M, most preferably about 25 μ M. It is contemplated that 15 lower or higher concentrations would also be effective. The tissue concentration may be derived from peptide blood levels.

The amount of active agent administered depends upon the degree of the infection. Those skilled in the art will derive appropriate dosages and schedules of administration to suit the specific circumstances 20 and needs of the patient. Doses are contemplated on the order of from about 0.01 to about 1, preferably from about 0.1 to about 0.5, mg/kg of body weight. The active agent may be administered by injection daily, over a course of therapy lasting two to three weeks, for example. Alternatively, the agent may be administered by continuous infusion, such as via an 25 implanted subcutaneous pumps.

Examples

A. Peptide Synthesis Procedure

The peptides of the invention, as well as other peptides prepared for comparison, were prepared synthetically as follows.

Peptides were prepared by solid phase peptide synthesis with Fmoc-strategy using a model 430A Applied Biosystems peptide synthesizer (Applied Biosystems, Foster City, CA) and Fmoc-tris (alkoxy) benzylamide liner (PAL-support) resin (Millipore, loading = 0.38mmole/g). The side chain-protecting groups of N^a-Fmoc amino acids were: Arg; Pmc, Asn; Trt, Asp; O'Bu, Cys; Trt, Gln; Trt, Glu; O'Bu, His; Trt, Lys; Boc, Ser; 'Bu and Thr; 'Bu (Pmc = 2,2,5,7,8-pentamethylchroman-6-sulfonyl, Trt = Trityl, O'Bu = tert-butyl ester, Boc = tert-butyloxycarbonyl and 'Bu = tert-butyl ether). N-Methyl-2-pyrrolidinone (NMP) was used as a solvent and 20 - 50% piperidine in NMP was used to remove the protected Fmoc groups. Initially, the resin (660mg, 0.25mmole) was swollen with NMP and treated with piperidine to remove the Fmoc group. The N^a-Fmoc amino acid (4 equiv.) activated with 2-(1 H-Benzotriazole-1-yl)1,1,3,3-tetra-methyluronium hexafluoro phosphate (HBTU) (4 equiv.) and diisopropylethylamine (DIPEA) (4 equiv.) was added to the resin for coupling followed by treatment with piperidine to remove the N-terminal Fmoc group. The coupling and deprotection steps were repeated for all the amino acid residues.

Upon completion of all synthetic cycles, resin was removed from the reaction vessel and treated with reagent K (King *et al.*, *Int. J. Pep. Prot. Res.* 36:255-266, (1990) (Trifluoroacetic acid (TFA):Phenol: thioanisole: ethanethiol: H₂O / 10: 0.75: 0.5: 0.25: 0.5) for 1.5 hour at room temperature with gentle stirring. The mixture was then filtered directly into ice-cold methyl t-butyl ether. The resulting suspension was transferred into a centrifuge tube and centrifuged for 10 min. at 2000 x g at room temperature. The supernatant was discarded and the precipitate was resuspended in methyl t-butyl ether, and again centrifuged for 5 minutes.

The procedure was repeated twice before the precipitate was dissolved in aqueous solvent and lyophilized.

The crude peptide was purified by preparative HPLC using Dynamax-300Å C18 column (241 x 22 mm I.D., 15mm spherical packing at 5 a flow rate of 9ml/min), with UV detection (220nm). Two HPLC solvents, solvent A (d.i. H₂O/0.1% TFA) and B (Acetonitrile/0.1% TFA) were used in a preprogrammed gradient. The fractions containing the peptide were pooled together and lyophilized.

The peptides were characterized by a procedure employing 10 analytical HPLC, Mass Spectrometry and finally high resolution 600 MHz NMR spectroscopy. These procedures ensure that the final synthetic products are of >99% purity.

B. Peptides

The following peptides were synthesized according to the above procedure:

		SEQ ID	
	<u>Example No.</u>	<u>NO:</u>	<u>Peptide</u>
5	1	4	Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn
10	2	5	Lys-Pro-Val-Ser-Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Gln-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn
15	3	6	Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn
20	4	7	Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Lys-Lys-Lys-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn
25	Comparative 1	8	Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe
30	Comparative 2	9	Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn
	Comparative 3	10-CONH ₂	Lys-Pro-Val-Ser-Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-CONH ₂

C. Biological Activity

5 A HIV-1 gp120-CXCR4 mediated cell-cell fusion assay was used to test the effect of the above peptides on HIV-1 virus entry via CXCR4. The assay is based upon the cell-cell fusion assay described by Rucker *et al.*, *Methods in Enzymology* 288:118-133 (1997) for studying the role of chemokine receptors in HIV-1 entry.

10 Effector and target cells were prepared as follows. HIV-1 Env proteins and T7 RNA polymerase were introduced into effector 293 cells by infection with recombinant vaccinia virus at a multiplicity of infection of 10 for 2 hours (the cell lines and HIV-1 isolates were kind gifts from R. W. 15 Doms of University of Pennsylvania). QT6 target cells were transfected in 6-well plates with plasmids encoding CD4, CXCR4 and luciferase under control of the T7 promoter, using the calcium phosphate precipitation method. Four to six hours after transfection, cells were lifted, washed with PBS, seeded in 24-well plates and incubated at 37°C overnight.

20 The effector and target cells were then subjected to fusion in the presence of SDF-1 peptide. To initiate fusion, 10⁵ effector cells were added to each well and incubated at 37°C in the presence of ara-C, rifampicin and SDF-1peptide (1 to 100 µM). After 5 hours of fusion, the 25 cells were lysed in 150 µl of reporter lysis buffer (Promega) and assayed for luciferase activity by commercially available reagents (luciferase assay substrate, Promega Cat. No. E151A; luciferase assay buffer, Promega Cat. No. E152A). The results for peptides SEQ ID NOS:4-8 and 10, as percent inhibition of cell-cell fusion at a peptide concentration of 25 µM, are set forth in Figure 1.

Each of the peptides SEQ ID NOS:4-7 contain segments from the N-terminal and C-terminal regions of SDF-1 linked through a homo-Gly or homo-Lys linker. Peptides SEQ ID NOS: 4, 6 and 7 correspond to SDF-1 amino acids 5-14 and 55-67, linked by a bridge of (Gly)₄, (Gly)₂, and

(Lys)₄, respectively. Peptide SEQ ID NO:5 corresponds to SDF-1 amino acids 1-14 and 55-67, linked by a (Gly)₄ bridge. The peptides of the invention (SEQ ID NOS:4, 5, 6 and 7) were substantially more effective in inhibiting cell-cell fusion than the N-terminal SDF-1 peptides SEQ ID NOS:8 and 10. The peptides of the invention were also more effective than the C-terminal SDF-1 peptide SEQ ID NO:9, which was only negligibly active at the higher concentration of 50 μ M.

The peptides of the invention are more effective in preventing CXCR4-mediated entry of HIV-1 in CXCR4-expressing cells, and are more effective HIV therapeutic agents.

All references discussed herein are incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

CLAIMS

1. A peptide of the formula



wherein:

X_1 is from zero to eight amino acids,

X_2 is three amino acids,

X_3 is from zero to eight amino acids,

L is a linker comprising a covalent bond or chemical moiety,

X_4 is from zero to eight amino acids,

X_5 is from zero to eight amino acids,

A is Ile, Leu, Phe or Val,

B is Ser or Thr

C is Phe, Tyr, or Trp,

D is Arg, His or Lys,

E is Arg, His or Lys,

F is Phe, Tyr, Trp or Leu

G is Phe, Tyr, Trp or Leu

J is Ile, Leu, Phe or Val,

K is Arg, Lys or His,

M is Phe, Tyr or Trp

N is Ile, Leu, Phe or Val,

P is Asn, Asp, Glu or Gln

Q is Asn, Asp, Glu or Gln

R is Tyr, Trp or Phe,

S is Ile, Leu, Phe or Val,

T is Asn, Asp, Glu or Gln

V is Arg, Lys or His,

W is Ile, Leu, Phe or Val,
Y is Asn, Asp, Glu or Gln, and
said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

2. A peptide of claim 2 wherein L is an amino acid sequence containing from 2 to 10 amino acids.
3. A peptide of d of claim 3 wherein L is an amino acid sequence containing from 2 to 6 amino acids.
4. A peptide of claim 4 wherein the amino acid sequence L is comprised of glycine or lysine amino acids.
5. A peptide of claim 1 wherein at least one amino acid residue is of the D-isomer configuration.
6. A compound of claim 3 wherein X_2 is Cys-Pro-Cys.
7. A compound of claim 1 wherein
A-B-C-D is Leu-Ser-Tyr-Arg,
E-F-G is Arg-Phe-Phe
J-K-M-N-P-Q-R-S-T-V is Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys, and
W-Y is Leu-Asn.
8. A peptide of claim 1 wherein
 X_1 is
 - (i) zero amino acids, or

(ii) the segment A¹-B¹-C¹-D¹ or N-terminal truncation fragment thereof containing at least one amino acid, wherein:

A¹ is Arg, Lys or His,
B¹ is Pro or N-methylalanine,
C¹ is Ile, Leu, Phe or Val, and
D¹ is Ser or Thr;

X₃ is

(i) zero amino acids, or
(ii) the segment A²-B²-C²-D²-Ala-E²-Ala-F², or C-terminal truncation fragment thereof containing at least one amino acid, wherein:

A² is Asn, Asp, Glu or Gln,
B² is Ser or Thr,
C² is Arg, Lys or His,
D² is Ile, Leu, Phe or Val,
E² is Arg, Lys or His,
F² is Asn, Asp, Glu or Gln;

X₄ is

(i) zero amino acids, or
(ii) the segment A³-B³-C³-D³, or N-terminal truncation fragment thereof containing at least one amino acid, wherein:

A³ is Ile, Leu, Phe or Val,
B³ is Asn, Asp, Glu or Gln,
C³ is Pro or N-methylalanine,
D³ is Arg, Lys or His; and

X_5 is zero amino acids.

9. A peptide of claim 8 wherein

the segment $A^1-B^1-C^1-D^1$ is Lys-Pro-Val-Ser (SEQ ID NO:1) or N-terminal truncation fragment thereof containing at least one amino acid;

the segment $A^2-B^2-C^2-D^2$ -Ala-E²-Ala-F² is Glu-Ser-His-Val-Ala-Arg-Ala-Asn (SEQ ID NO:2), or C-terminal truncation fragment thereof containing at least one amino acid; and

the segment $A^3-B^3-C^3-D^3$ is Ile-Asp-Pro-Lys (SEQ ID NO:3), or C-terminal truncation fragment thereof containing at least one amino acid.

10. A peptide of claim 9 wherein X_2 is Cys-Pro-Cys.

11. A peptide of claim 10 wherein L is an amino acid sequence containing from 2 to 10 amino acids.

12. A peptide of claim 11 wherein the amino acid sequence L is comprised of glycine or lysine amino acids.

13. The peptide of claim 12 which has the amino acid sequence Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn (SEQ ID NO:4) and optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

14. The peptide of claim 12 which has the amino acid sequence Lys-Pro-Val-Ser-Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn (SEQ ID NO:5) and optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

15. The peptide of claim 12 which has the amino acid sequence Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Gly-Gly-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn (SEQ ID NO:6) and optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

16. The peptide of claim 12 which has the amino acid sequence Leu-Ser-Tyr-Arg-Cys-Pro-Cys-Arg-Phe-Phe-Lys-Lys-Lys-Leu-Lys-Trp-Ile-Gln-Glu-Tyr-Leu-Glu-Lys-Ala-Leu-Asn (SEQ ID NO:7) and optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide of claim 1.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide of claim 8.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the peptide of claim 13.

20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the peptide of claim 14.

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the peptide of claim 15.

22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the peptide of claim 16.

23. A method of inhibiting entry of HIV-1 into CXCR4-expressing cells comprising contact said cells with a peptide according to claim 1.

24. A method of inhibiting entry of HIV-1 into CXCR4-expressing cells comprising contact said cells with a peptide according to claim 8.

25. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 1.

26. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 8.

27. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 13.

28. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 14.

29. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 15.

30. A method of treating infection by HIV-1 comprising administering to an individual an effective amount of a peptide according to claim 16.

31. A synthetic chemokine peptide having an amino acid sequence derived from a naturally occurring chemokine comprising:

(a) an N-terminal segment comprising a sequence of from about 10 to about 25 amino acids, which N-terminal segment has at least about 50% sequence identity with a first reference segment of a naturally occurring chemokine, said first reference segment being found in the N-terminal region of said naturally occurring chemokine;

(b) a C-terminal segment comprising a sequence of from about 10 to about 25 amino acids, which C-terminal segment has at least about 50% sequence identity with a second reference segment of the naturally occurring chemokine, said second reference segment being found in the C-terminal region of the naturally occurring chemokine; and

(c) a linker comprising a covalent bond or chemical moiety linking the C-terminus of said N-terminal segment to the N-terminus of said C-terminal segment.

32. A synthetic chemokine peptide according to claim 31 wherein:

the N-terminal segment has at least about 80% sequence identity with the first reference segment of the naturally occurring chemokine;

the C-terminal segment has at least about 80% sequence identity with the second reference segment of the naturally occurring chemokine; and

the linker is an amino acid sequence containing from 2 to 10 amino acids.

33. A synthetic chemokine peptide according to claim 32 wherein:

the N-terminal segment has at least about 90% sequence identity with the first reference segment of the naturally occurring chemokine;


the C-terminal segment has at least about 90% sequence identity with the second reference segment of the naturally occurring chemokine; and

the linker is an amino acid sequence containing from 2 to 6 amino acids.

34. A synthetic chemokine peptide according to claim 32 wherein:

the amino acid sequence of the N-terminal segment differs from the first reference segment of the naturally occurring chemokine only by conservative amino acid substitutions; and

the amino acid sequence of the C-terminal segment differs from the second reference segment of the naturally occurring chemokine only by conservative amino acid substitutions.



<110> Thomas Jefferson University

<120> Chemokine-Derived Synthetic Peptides

<130> 8321-40 PC

<140>

<141>

<150> 60/128,106

<151> 1999-04-07

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Segment from
N-terminal region of human SDF-1 protein

<400> 1

Lys Pro Val Ser

1

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Segment from
N-terminal region of human SDF-1 protein

<400> 2

Glu Ser His Val Ala Arg Ala Asn

1

5

<210> 3

<211> 4

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Segment from
C-terminal region of human SDF-1 protein

<400> 3

Ile Asp Pro Lys

1

<210> 4

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide containing segments from N- and C-terminal
regions of human SDF-1 protein

<400> 4

Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly Gly Leu Lys
1 5 10 15

Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn

20 25

<210> 5

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide containing segments from N- and C-terminal
regions of human SDF-1 protein

<400> 5

Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
1 5 10 15

Gln Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn

20 25 30

<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide containing segments from N- and C-terminal regions of human SDF-1 protein

<400> 6
Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly Leu Lys Trp Ile
1 5 10 15

Gln Glu Tyr Leu Glu Lys Ala Leu Asn
20 25

<210> 7
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide containing segments from N- and C-terminal regions of human SDF-1 protein

<400> 7
Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Lys Lys Lys Lys Leu Lys
1 5 10 15

Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
20 25

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide containing segment from N-terminal region of human SDF-1 protein

<400> 8
Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe

1 5 10

<210> 9
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide containing segment from C-terminal region of human SDF-1 protein

<400> 9
Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
1 5 10

<210> 10
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide containing segment from N-terminal region of human SDF-1 protein

<400> 10
Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe
1 5 10

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Segment from N-terminal region of human SDF-1 protein

<400> 11
Leu Ser Tyr Arg
1

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ence: Segment
from C-terminal region of human SDF-1 protein

<400> 12

Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
1 5 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/09236

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 2/00, 14/00; A61K 38/19, 48/00

US CL : 530/350, 351, 300; 424/85.1; 514/44, 2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 351, 300; 424/85.1; 514/44, 2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/11655 A1(GRYPHON SCIENCES) 11 March 1999 (11. 04. 99), see entire document.	1-34

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
A	Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
C	earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
D	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
E	document referring to an oral disclosure, use, exhibition or other means		
F	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
03 JULY 2000	04 AUG 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer NIRMAL S. BASI Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/09236

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

US PATENTS, JPO ABSTRACTS, EPO ABSTRACTS, EMBASE, CAPLUS, MEDLINE, SCISEARCH, BIOSIS,
WPIDS, A-GENESEQ35, PIR62, SWISS-PROT38, SPTREMBL12
search terms: seq id nos 1-12, hiv-1, chemokine, cxcrx